Toripalimab plus chemotherapy as first-line treatment in extensive-stage small cell lung cancer: a health economic evaluation in China.

ABSTRACT:

Objective

To assess the cost-effectiveness of toripalimab plus etoposide and platinum (EP)-based chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) from a Chinese healthcare system perspective, and to explore the impact of factors such as biomarker stratification, drug wastage, and drug donation on cost-effectiveness.

Methods

A partitioned survival model was conducted to simulate the disease progression in ES-SCLC patients. Model parameters were derived from the EXTENTORCH clinical trial, public databases, and published literature. Key outcomes included total cost, quality-adjusted life years (QALYs), incremental cost-effectiveness ratio (ICER), and incremental net monetary benefit (INMB). Drug wastage was quantified based on body sur

SUBMITTER: Zhu J 

PROVIDER: S-EPMC12711754 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature